Surgical adhesions are a significant postoperative complication affecting millions of patients globally, contributing to chronic pain, infertility, bowel obstruction, and increased reoperation rates. Clinicians and surgeons continually seek effective methods to minimize adhesion formation, with meticulous tissue-handling strategies remaining a cornerstone of prevention. This review synthesizes recent evidence and guidelines regarding the epidemiology, pathophysiology, risk factors, clinical features, diagnostic approach, and advanced management of surgical adhesions, with a dedicated focus on intraoperative tissue-handling techniques. Emphasis is placed on mechanism-based rationale and practical implications for surgeons aiming to optimize patient outcomes.
Postoperative adhesions develop following most abdominal and pelvic surgeries, posing a persistent challenge for surgeons and a substantial burden to healthcare systems. Despite technological advances and barrier agents, adhesion prevention remains elusive, with tissue-handling strategies forming the foundation of surgical best practices. Understanding the mechanisms underlying adhesion formation and implementing evidence-based interventions during surgery are essential for reducing postoperative morbidity.
Surgical adhesions occur in up to 93% of patients undergoing major abdominal or pelvic surgery. They account for 60–70% of small bowel obstructions and are implicated in 20–40% of infertility cases in women with prior pelvic surgery. Adhesion-related complications result in significant morbidity, repeated hospitalizations, increased healthcare costs, and diminished quality of life. In the United States alone, the annual cost attributed to adhesion-related readmissions exceeds $2 billion. The prevalence remains high despite minimally invasive approaches, underscoring the importance of comprehensive prevention strategies.
Adhesion formation is initiated by peritoneal injury, which disrupts mesothelial integrity and triggers a cascade of inflammatory, fibrinogenic, and repair processes. Tissue trauma, ischemia, and desiccation lead to exudation of fibrin-rich fluid. Under normal conditions, fibrinolysis rapidly resolves fibrin deposits; however, surgical trauma, infection, or ischemia can impair this process, resulting in permanent fibrous adhesions. The interplay between cytokine release, cellular infiltration, and extracellular matrix remodeling determines the extent of adhesion development. Mechanical factors such as foreign bodies, suture materials, and thermal injury further potentiate adhesion risk.
Several factors enhance adhesion propensity, including the type and duration of surgery, the presence of infection or inflammation, use of certain energy devices, and prior surgical history. Open procedures, extensive tissue dissection, and repeated interventions increase risk. Patient-specific factors such as genetic predisposition, diabetes, and connective tissue disorders may also play a role. Identification of modifiable intraoperative and patient-related risk factors is essential for targeted prevention.
Adhesions often remain asymptomatic but can manifest as chronic abdominal or pelvic pain, infertility, and bowel obstruction. Clinical presentation may be delayed, with symptoms developing months to years postoperatively. Adhesion-related small bowel obstructions present with abdominal pain, vomiting, distension, and constipation. Gynecological adhesions are associated with subfertility, dysmenorrhea, and dyspareunia. The nonspecific nature of symptoms poses diagnostic challenges, necessitating a high index of clinical suspicion in at-risk individuals.
Diagnosis of adhesions is primarily clinical and based on history and presentation, as there are no pathognomonic imaging findings. Conventional radiography and computed tomography (CT) may suggest obstruction but cannot directly visualize adhesions. Magnetic resonance imaging (MRI) and cine-MRI offer improved soft-tissue contrast but have limited sensitivity. Laparoscopy remains the gold standard for definitive diagnosis and allows for therapeutic intervention. Non-invasive diagnostic modalities are under investigation, emphasizing the need for better biomarkers and imaging techniques.
Management of adhesions is largely supportive and symptom-driven. Conservative approaches, including bowel rest, nasogastric decompression, and fluid resuscitation, are first-line for uncomplicated adhesive small bowel obstruction. Surgical intervention adhesiolysis is reserved for refractory or complicated cases but carries a risk of recurrence and inadvertent enterotomy. Preventive strategies are paramount, with intraoperative attention to tissue handling, judicious use of foreign materials, and minimization of peritoneal trauma. Pharmacological agents and barrier products offer adjunctive benefits but are not substitutes for meticulous surgical technique.
Recent advances in adhesion prevention include the development of novel barrier agents (e.g., hyaluronate-carboxymethylcellulose membranes, polyethylene glycol hydrogels), anti-inflammatory drugs, and fibrinolytic agents. Innovations in surgical instrumentation, energy devices, and minimally invasive techniques seek to reduce peritoneal trauma. However, meta-analyses suggest that no single intervention is universally effective, and combined approaches yield the best outcomes. Ongoing research focuses on targeted molecular therapies and improved biomaterials for adhesion prophylaxis.
Current guidelines from surgical and gynecological societies emphasize the pivotal role of tissue-handling strategies in adhesion prevention. Recommendations include avoiding unnecessary tissue manipulation, minimizing desiccation and ischemia, using atraumatic instruments, ensuring meticulous hemostasis, and maintaining normothermia. Surgeons are advised to employ barrier agents in high-risk cases and to select the least traumatic surgical approach feasible. Adherence to evidence-based protocols is essential to optimize outcomes and reduce the burden of adhesions.
Prevention of surgical adhesions requires a multifaceted approach, with meticulous tissue-handling strategies forming the foundation of effective prophylaxis. Awareness of risk factors, adherence to guideline-based recommendations, and judicious use of adjunctive therapies are critical for minimizing adhesion-related morbidity. Ongoing research and innovation hold promise for more targeted and effective interventions. For practicing surgeons, prioritizing gentle, evidence-based tissue handling remains the most impactful measure to safeguard patient outcomes and reduce the global burden of postoperative adhesions.
1.
For MDS-Related Anemia, Telomerase Inhibitor Approved.
2.
Efficacy and safety of intravenous chemotherapy in children with intraocular retinoblastoma
3.
Admissions, medical schools, costs, and eligibility requirements information for FNB Onco-Anesthesia.
4.
Treating Depression: Crucial for Recovery From Fibromyalgia
5.
In postmenopausal women with hormone receptor-positive tumors, obesity increases the risk of breast cancer recurrence.
1.
Empowering Oncology with Data: Cloud Security, Real-World Evidence, and Clinical Insights
2.
Immune Regulation of Blood Cell Development
3.
Exploring the Effects of Radiation Therapy on Cystitis: A Journey to Better Health
4.
Transformative Frameworks in Oncology for Better Care
5.
Liposomal Doxorubicin and Mitomycin in Modern Cancer Treatment
1.
International Conference on Oncology, Cancer Prevention and Public Health
2.
International Conference on Cancer Nursing and Rehabilitation Strategies
3.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
4.
International Conference on Innovations in Critical Care for Oncology and Cardiology
5.
International Symposium on Oncology, Cardiology and Critical Care Innovations
1.
Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment
2.
Newer Immunotherapies for Myeloma- A Comprehensive Overview
3.
Understanding the causes of anemia in adults beyond nutritional deficiencies
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part III
5.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation